Merus Announces $55.8 Million Private Placement Offering of Common Stock Read more about Merus Announces $55.8 Million Private Placement Offering of Common Stock
Merus Announces Participation in Four Investor Conferences in February 2018 Read more about Merus Announces Participation in Four Investor Conferences in February 2018
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations Read more about Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies Read more about Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs Read more about Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference Read more about Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron Read more about Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Merus to Present at the Jefferies London Healthcare Conference Read more about Merus to Present at the Jefferies London Healthcare Conference
Merus to Participate in the BIO Investor Forum Read more about Merus to Participate in the BIO Investor Forum
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology Read more about Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology